Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if INKT is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
2 top institutions tracked
Sentiment: unknown
No recent insider trades detected.
Red flags: 8
27 filers reported a long position in INKT for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $802.6K | 68.7K | +15.7% |
| DnB Asset Management AS | $644.6K | 55.1K | New |
| Longbow Finance SA | $194.8K | 16.7K | Unchanged |
| GEODE CAPITAL MANAGEMENT, LLC | $182.1K | 15.6K | -10.2% |
| CITADEL ADVISORS LLC | $180.5K | 15.4K | New |
| BlackRock, Inc. | $156.4K | 13.4K | +115.7% |
| VANGUARD FIDUCIARY TRUST CO | $96.9K | 8.3K | Unchanged |
| UBS Group AG | $57.1K | 4.9K | -67.9% |
| Steward Partners Investment Advisory, LLC | $23.4K | 2K | Unchanged |
| US BANCORP \DE\ | $23.3K | 2K | New |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.